Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL14441307 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL17359656 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL16072074 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13294189 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL14430016 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL18838926 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22356672 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13014098 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464789-B2 | Aminosterol compositions and methods of using the same for treating schizophrenia | ENTERIN, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210338691-A1 | METHODS FOR TREATING SLEEP DISORDERS, SLEEP DISTURBANCES, AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210315907-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS | Enterin, Inc, (US) | 2021-10-14 | — | — | US | disclosed |
| US-11083735-B2 | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions | ENTERIN, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200155574-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING SCHIZOPHRENIA | ENTERIN, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200129528-A1 | METHODS FOR TREATING BLOOD PRESSURE CONDITIONS USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200038416-A1 | METHODS OF TREATING CARDIAC CONDUCTION DEFECTS USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038419-A1 | METHODS OF TREATING MULTIPLE SYSTEM ATROPHY USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038415-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING ERECTILE DYSFUNCTION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038413-A1 | METHODS OF TREATING PARKINSON'S DISEASE USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038417-A1 | METHODS AND COMPOSITIONS FOR TREATING COGNITIVE IMPAIRMENT | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038412-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038418-A1 | METHODS OF TREATING AUTISM SPECTRUM DISORDER USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038414-A1 | METHODS OF TREATING CONSTIPATION USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190298740-A1 | METHODS AND COMPOSITIONS FOR TREATING HALLUCINATIONS AND CONDITIONS RELATED TO THE SAME | ENTERIN, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190091241-A1 | METHODS FOR TREATING SLEEP DISORDERS, SLEEP DISTURBANCES, AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS | ENTERIN, INC. (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038418-A1 | METHODS OF TREATING AUTISM SPECTRUM DISORDER USING AMINOSTEROL COMPOSITIONS | CYP17A1, HSD17B7, HSD17B2 | PTPN1 3974/4885NR1H4 229/4885SLC10A1 505/4885 |
| US-20200038413-A1 | METHODS OF TREATING PARKINSON'S DISEASE USING AMINOSTEROL COMPOSITIONS | SNCA, PARK7, HMGCR | PTPN1 3403/4885NR1H4 684/4885SLC10A1 283/4885 |
| US-20200155574-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING SCHIZOPHRENIA | HSD17B7, HSD17B13, NR3C2 | PTPN1 3269/4885NR1H4 389/4885SLC10A1 369/4885 |
| US-20210315907-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS | SLC10A2, FABP2, FABP7 | PTPN1 3943/4885NR1H4 52/4885SLC10A1 8/4885 |
| US-20200038414-A1 | METHODS OF TREATING CONSTIPATION USING AMINOSTEROL COMPOSITIONS | SLC10A2, CYP51A1, SI | PTPN1 4665/4885NR1H4 9/4885SLC10A1 82/4885 |
| US-20190091241-A1 | METHODS FOR TREATING SLEEP DISORDERS, SLEEP DISTURBANCES, AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS | HSD3B1, HSD3B2, CYP21A2 | PTPN1 4259/4885NR1H4 50/4885SLC10A1 242/4885 |
| US-20200038417-A1 | METHODS AND COMPOSITIONS FOR TREATING COGNITIVE IMPAIRMENT | CHAT, BCHE, PSEN2 | PTPN1 4836/4885NR1H4 228/4885SLC10A1 381/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | PTPN1 4123/4885NR1H4 526/4885SLC10A1 463/4885 |
| US-20210338691-A1 | METHODS FOR TREATING SLEEP DISORDERS, SLEEP DISTURBANCES, AND RELATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS | HSD3B1, HSD3B2, CYP21A2 | PTPN1 4259/4885NR1H4 50/4885SLC10A1 242/4885 |
| US-20200038412-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING AMINOSTEROL COMPOSITIONS | PSEN1, PSEN2, APP | PTPN1 4701/4885NR1H4 148/4885SLC10A1 183/4885 |
| US-20200038415-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING ERECTILE DYSFUNCTION | PDE3A, CYP17A1, PDE3B | PTPN1 3927/4885NR1H4 859/4885SLC10A1 802/4885 |
| US-20200038416-A1 | METHODS OF TREATING CARDIAC CONDUCTION DEFECTS USING AMINOSTEROL COMPOSITIONS | LSS, CYP27A1, TNNC1 | PTPN1 3106/4885NR1H4 772/4885SLC10A1 275/4885 |
| US-11464789-B2 | Aminosterol compositions and methods of using the same for treating schizophrenia | HSD17B7, HSD17B13, NR3C2 | PTPN1 3269/4885NR1H4 389/4885SLC10A1 369/4885 |
| US-11083735-B2 | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions | HSD3B1, HSD3B2, CYP21A2 | PTPN1 4259/4885NR1H4 50/4885SLC10A1 242/4885 |
| US-20190298740-A1 | METHODS AND COMPOSITIONS FOR TREATING HALLUCINATIONS AND CONDITIONS RELATED TO THE SAME | GABBR1, GABBR2, SLC6A11 | PTPN1 4253/4885NR1H4 835/4885SLC10A1 687/4885 |
| US-20200129528-A1 | METHODS FOR TREATING BLOOD PRESSURE CONDITIONS USING AMINOSTEROL COMPOSITIONS | HMGCR, HSD11B2, CYP11B1 | PTPN1 3211/4885NR1H4 282/4885SLC10A1 56/4885 |
| US-20200038419-A1 | METHODS OF TREATING MULTIPLE SYSTEM ATROPHY USING AMINOSTEROL COMPOSITIONS | SNCA, SMN1; SMN2, PMP22 | PTPN1 4359/4885NR1H4 884/4885SLC10A1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.